The process of creating a new drug is hard and takes a long time. It includes steps like finding the cause of the disease, discovering molecules that might help, testing in labs, running clinical trials, and getting approval from regulators. Each step can take many years. Also, about 90% of drug candidates fail before they get approved because of safety or effectiveness problems found late. These failures raise costs and slow down treatment availability.<\/p>\n
Because of these problems, drug companies are under pressure to find new ways to work. Delays in making drugs mean patients wait longer, and high costs can make treatments expensive. Healthcare managers in the U.S. may see these delays affect patient demands and how they work with drug companies on trials or new drug information.<\/p>\n
AI technologies like machine learning, deep learning, natural language processing, and generative AI help solve many problems in drug discovery. These AI tools look at large sets of health data quickly and accurately. They find patterns and guess how molecules will act. This lets researchers move faster and cut down on costly mistakes.<\/p>\n
In real use, AI helps with:<\/p>\n
For example, Insilico Medicine used AI to create inhibitors for hard-to-treat cancers and got lab results faster than usual. Atomwise found a possible Ebola treatment in days instead of months or years. These examples show AI can shorten drug discovery time and cut costs.<\/p>\n
Usually, making a new drug takes over ten years and costs about $1 billion. AI can cut that time and cost a lot. Research shows AI lowers failure rates by better guessing drug safety and effectiveness, which reduces expensive late failures.<\/p>\n
Experts say the AI drug market will grow from $13.8 billion in 2022 to $164.1 billion by 2029. There are over 900 FDA-approved AI medical devices now. Big drug companies like Johnson & Johnson, AbbVie, Eli Lilly, and Pfizer are using AI to speed up finding drug targets, designing molecules, and recruiting patients for trials.<\/p>\n
AbbVie\u2019s AI platform, ARCH, mixes different data to design drugs by computer and find patient-specific markers. Johnson & Johnson uses AI to find molecules faster and improve patient recruitment, helping tailor care.<\/p>\n
AI use is not just for big companies. Clinics and labs across the U.S. may soon get faster drug access and work easier with drug trials because of AI.<\/p>\n
AI does more than speed things up or save money. It helps make better and more precise medicines:<\/p>\n
AI platforms have also found groups of patients who react best to certain treatments, supporting safer and more targeted care. This fits with the U.S. move toward value-based care, which focuses on treatment results and patient needs.<\/p>\n
Even with its benefits, AI faces some problems before becoming common in drug development:<\/p>\n
Health IT managers and practice administrators need to know about these issues since they affect how AI treatments get used and how data sharing with drug companies works.<\/p>\n
<\/p>\n